Fibrates News and Research

RSS

Fenofibrate intervention and event lowering in diabetes

Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision.

6 Nov 2007

Abbott and AstraZeneca confirm Phase III clinical trials of Fenofibrate ABT-335 and Crestor as fixed-dose combination

Abbott and AstraZeneca confirmed they will advance the development of Abbott's next-generation fenofibrate ABT-335 and AstraZeneca's CRESTOR (rosuvastatin calcium) in a fixed-dose combination treatment into Phase III clinical trials.

3 Sep 2007

Caution urged on use of drugs to raise "good" cholesterol

With 40 percent of all heart attacks and related cardiovascular problems occurring in people who have low levels of so-called "good" cholesterol, researchers have long sought medications to increase the amount of this type of cholesterol in the body's circulation.

16 Aug 2007

Regular exercise increases "good" cholesterol

Regular exercise appears to modestly increase levels of high-density lipoprotein, or "good," cholesterol, according to a meta-analysis study in the May 28 issue of Archives of Internal Medicine , one of the JAMA/Archives journals.

30 May 2007

New drug combo to cut cardiovascular disease

A major international study to test whether a new combination treatment that increases good "HDL" cholesterol prevents heart attacks and strokes will start to recruit patients later this year.

6 Jun 2006

Cholesterol lowering drugs, including statins, may slow the progression of Alzheimer's disease

Cholesterol lowering drugs, including statins, may slow the progression of Alzheimer's disease, concludes a study in the Journal of Neurology Neurosurgery and Psychiatry.

20 Nov 2005

Cholesterol lowering drugs do not appear to decrease the risk of melanoma

No clear evidence exists that some widely-prescribed cholesterol-lowering drugs can decrease the risk of melanoma, a deadly and malignant skin cancer, according to a new review of recent studies.

7 Nov 2005

Actos reduces the combined risk of non-fatal heart attacks, strokes in patients with type-2 diabetes

A study published in The Lancet shows that Takeda's Actos (pioglitazone HCl), an oral glucose lowering medication, significantly reduces the combined risk of non-fatal heart attacks, strokes and deaths by an additional 16% on top of standard medication

10 Oct 2005

HDL cholesterol helps prevent blocked arteries and heart attack

Cardiology experts at Johns Hopkins have issued interim guidelines for physicians on how best to treat low levels of HDL cholesterol, the so-called good cholesterol, which helps keep arteries clear from the buildup of LDL cholesterol, the so-called bad cholesterol.

22 Sep 2005

Information about serious adverse effects of cerivastatin were known within months after drug launched

A review of the published literature and of internal company documents from the manufacturer of cerivastatin, a cholesterol lowering drug removed from the market in 2001, suggests that information about serious adverse effects of this medication was known to the company within months after this drug was launched

23 Nov 2004

Patients taking the lipid-lowering medications have a relatively low risk of developing rhabdomyolysis

Patients taking the lipid-lowering medications atorvastatin, pravastatin, and simvastatin to reduce cholesterol levels, have a relatively low risk of developing rhabdomyolysis, (a disorder that causes the breakdown of muscle), according to a new study in the December 1 issue of JAMA.

23 Nov 2004

Zetia co-administered with Fenofibrate significantly reduced LDL ("bad") cholesterol in mixed hyperlipidemia patients

Results from a new study showed that coadministration of Zetia (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C) and apo B1 in patients with mixed hyperlipidemia and high LDL cholesterol when compared to fenofibrate alone.

9 Nov 2004

First Approval in Europe of Ezetimibe/Simvastatin for treatment of elevated cholesterol

Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad’ cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU’s mutual recognition procedure.

4 Apr 2004